Jiang Xi Sanxin Medtec Co Ltd Class A

Jiang Xi Sanxin Medtec Co Ltd Class A

SSZSE:300453
9.64
CNY
+0.10
(+1.05%)
0.61EPS
16.06P/E
4.72BMarket Cap
Mar 22Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.78
0.83
0.62
0.61
0.78
1.01
1.37
1.84
2.26
2.59
2.51
2.91
3.17
3.45
Basic EPS, GAAP
0.13
0.13
0.1
0.07
0.08
0.08
0.12
0.23
0.3
0.36
0.4
0.44
0.51
0.56
Free Cash Flow per Basic Share
-0.05
0.05
-0.01
-0.1
-0.05
-0.14
0.08
0.34
0.3
0.37
0.1
0.33
0.42
- -
Dividend per Share
0.01
0.03
- -
0.03
0.03
0.03
0.04
0.05
0.1
0.12
0.12
0.26
0.32
0.32
Book Value per Share
0.53
0.64
1.02
1.06
1.11
1.13
1.24
1.46
1.74
2.05
2.4
2.53
2.79
2.96
Tangible Book Value per Share
0.44
0.54
0.93
0.97
1.02
1.03
0.93
1.13
1.39
1.64
1.97
2.12
2.35
2.51
Basic Weighted Avg Shares
389
389
500
522
515
527
527
511
515
515
518
515
518
515
Sales/Revenue/Turnover
305
322
312
318
404
531
722
940
1,164
1,336
1,300
1,500
1,640
1,778
Operating Margin (%)
19.57
17.61
16.66
13.14
11.66
9.09
11.53
16.3
17.24
16.93
18.98
18.89
19.92
20.41
Depreciation Expense
10
12
14
16
20
29
35
50
58
66
74
91
121
- -
Net Income, GAAP
49
49
52
37
42
41
62
116
156
185
207
227
265
290
Effective Tax Rate (%)
14.52
13.86
14.08
13.2
14.38
15.13
12.8
16.05
12.06
11.75
11.69
10.27
10.48
9.65
Profit Margin (%)
15.96
15.09
16.64
11.52
10.5
7.74
8.55
12.3
13.39
13.82
15.89
15.16
16.15
16.33
Working Capital
40
30
271
223
183
122
39
108
169
160
127
246
316
720
LT Debt
11
- -
- -
- -
- -
- -
12
5
3
48
82
158
181
659
Total Equity
208
250
532
553
582
610
718
845
979
1,155
1,334
1,409
1,554
1,627
Return on Invested Capital (%)
17.83
14.8
10.47
6.95
7.38
6.37
8.68
14.2
17.19
17.55
16.07
15.65
16.89
15.79
Return on Capital (%)
20.44
17.43
12.42
6.75
7.54
6.74
8.03
11.33
14.29
14.99
13.75
13.19
14.07
13.32
Return on Common Equity (%)
26.54
21.24
13.27
6.75
7.49
6.94
9.67
15.9
18.44
18.63
17.79
17.69
19.04
20.07

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
43
65
64
LT Borrowings
171
171
650
LT Finance Leases
9
9
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
522
522
522
Market Capitalization
5,148
4,720
4,725

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
918
907
1,392
Cash, Cash Equivalents & STI
519
524
989
Accounts Receivable, Net
87
80
87
Inventories
241
260
279
Total Current Liabilities
562
638
672
Payables & Accruals
- -
- -
- -
ST Debt
43
65
64
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.46%
13.04%
10.29%
Free Cash Flow
157.96%
39.1%
27.13%
Net Income, GAAP
21.25%
18.35%
16.51%
Sales/Revenue/Turnover
18.73%
12.12%
9.31%
Total Cash Common Dividend
- -
48.16%
23.71%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
331
355
396
418
1,500
2025
361
400
- -
473
1,640
2026
409
428
468
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.1
0.12
0.12
0.44
2025
0.1
0.12
- -
0.16
0.51
2026
0.13
0.12
0.15
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.15
0.11
- -
0.26
2025
- -
0.21
- -
- -
0.32
2026
- -
0.21
0.1
- -
- -

Company Description

CEO
Zhiping Mao
Full Time Employees
2,297
Sector
Health technology
Industry
Medical specialties
Address
No. 999 Fushan Road Nanchang JX China 330200
IPO Date
May 5, 2015
Business
Jiangxi Sanxin Medtec Co., Ltd. (300453.SZ) develops, manufactures, and sells medical devices with a focus on blood purification solutions; it offers core products including dialysate filters, dialysis indwelling needles, hemodialysis machines, centralized dialysate supply systems, hemodialysis water preparation systems, hollow fiber hemodialyzers, sterile hemodialysis blood circuits, tubing sets for hemodialysis, hemodialysis powders and concentrates, arteriovenous spikes, and nursing kits for dialysis; infusion and transfusion sets such as light-resistant infusion sets, TPE precise filter infusion sets, auto-stop fluid precise filter infusion sets, catheter infusion sets, and transfusion sets; indwelling catheters comprising straight, Y-type, closed, and positive pressure IV catheters, central venous catheter packs, extension tubes with three-way valves, and heparin caps; injection devices including insulin, dispenser, sterile, auto-disable syringes, fixed-dose immunization syringes, hypodermic needles, needleless injection systems, and pneumatic syringes; cardiothoracic surgery products such as blood microembolus filters, disposable extracorporeal circulation tubing kits, cold cardioplegic solution perfusion apparatus, and blood containers; as well as protective items like medical surgical face masks, disinfectants, and alcohol pads. Founded in 1997 and headquartered in Nanchang, Jiangxi Province, China, at No. 999 Fushan Avenue, Xiaolan Economic Development Zone, the company operates eight intelligent production bases and serves markets in over 100 countries and regions, holding more than 200 patents, over 100 product registrations, and participation in 10 national and industry standards; it has obtained CE, CMD, and US FDA 510K certifications. In recent developments, the company received approval in 2025 for China's first domestically-produced hemodialysis concentrates containing citric acid and a catheter flush device; it launched needle-free syringes for diabetes management and advanced early chronic kidney disease solutions via subsidiary Shengdankan, including a colon dialysis machine and sterile rectal catheters; additionally, it showcased innovations in hemodialysis, infusion therapy, diabetes management, and vascular access at CMEF 2025 and reported semi-annual revenue of 400.23 million CNY with net income of 67.81 million CNY in 2025.